Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JK08 + lenvatinib
- Development stage
- Unknown
- Lead developer
- Salubris Biotherapeutics Inc
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
JK08 + lenvatinib is an experimental combination therapy in which **JK08**, a novel investigational agent with ongoing clinical evaluation, is administered in combination with **lenvatinib** (a multikinase inhibitor targeting angiogenesis-related and growth factor receptors). This combination is being tested in patients with unresectable, locally advanced or metastatic cancer, including hepatocellular carcinoma, in early-phase clinical trials. Lenvatinib inhibits the kinase activities of VEGF receptors (VEGFR1, VEGFR2, VEGFR3), FGFR1-4, PDGFRα, KIT, and RET, thereby blocking signaling pathways associated with cancer development and progression. The precise mechanism and molecular target of JK08 is not described in available sources. The combination aims to enhance antitumor activity by targeting complementary pathways involved in tumor growth and the tumor microenvironment[1][2][3].
- Other names
- lenvatiniblenvatinib mesylate
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR3 (Fibroblast growth factor receptor 3)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on JK08 + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JK08 + lenvatinib.